These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1202532)

  • 41. Intravenous prostavasin--therapy in peripheral arterial occlusive disease in Fontaine's stages III and IV. Early and late results of a screening study.
    Heidrich H; Meuche C; Ranft J; Rummel S; Peters A
    Prog Clin Biol Res; 1989; 301():411-6. PubMed ID: 2678131
    [No Abstract]   [Full Text] [Related]  

  • 42. [Behavior of blood coagulation factors under the effect of a new pyrazol derivative during prolonged anticoagulant therapy].
    Wolf H
    Arzneimittelforschung; 1970 Sep; 20(9):1252-8. PubMed ID: 4098759
    [No Abstract]   [Full Text] [Related]  

  • 43. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke.
    Elger B; Laux V; Schwarz M
    Arzneimittelforschung; 1997 Aug; 47(8):895-9. PubMed ID: 9296273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rheological studies of creep and creep recovery of unligated fibrin clots: comparison of clots prepared with thrombin and ancrod.
    Bale MD; Müller MF; Ferry JD
    Biopolymers; 1985 Mar; 24(3):461-82. PubMed ID: 3986291
    [No Abstract]   [Full Text] [Related]  

  • 46. Thrombolytic therapy for venous thrombosis in patients with gastro-intestinal diseases.
    Pogliani EM; Bozzani A; Radaelli F; Conte D; Bardella MT; Colombi M; Quatrini M
    Pharmatherapeutica; 1982; 3(4):268-73. PubMed ID: 6755491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Fibrinolytic and defibrinogenation therapy].
    Mannucci PM; Mari D
    Ric Clin Lab; 1983; 13 Suppl 3():245-55. PubMed ID: 6672998
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Heparin. Mode of action, indications, administration].
    Kierulf P
    Tidsskr Nor Laegeforen; 1971 Oct; 91(29):2105-8. PubMed ID: 5130881
    [No Abstract]   [Full Text] [Related]  

  • 50. A report on the use of Arvin in patients with pre-gangrene of the lower limb.
    Humphreys WV; Walker A; Charlesworth D
    Br J Surg; 1977 Jan; 64(1):31-3. PubMed ID: 831951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Defibrination with ancrod (arvin) in peripheral arterial occlusive diseases. Principle, indications, contraindications technic and course].
    Heidrich H
    ZFA (Stuttgart); 1978 Nov; 54(32):1648-51. PubMed ID: 735320
    [No Abstract]   [Full Text] [Related]  

  • 52. On thrombosis, thrombolysis and fibrinolysis. I. Thrombolytic therapy of deep venous thrombosis. II. Assay of individual fibrinolytic response.
    Robertson BR
    Acta Chir Scand Suppl; 1971; 421():1-51. PubMed ID: 5292287
    [No Abstract]   [Full Text] [Related]  

  • 53. Ancrod.
    Sherman DG
    Curr Med Res Opin; 2002; 18 Suppl 2():s48-52. PubMed ID: 12365829
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Dosage of urokinase in venous thrombosis of the lower extremities].
    Zimmermann R; Harenberg J
    Dtsch Med Wochenschr; 1980 Aug; 105(35):1228. PubMed ID: 7000484
    [No Abstract]   [Full Text] [Related]  

  • 55. [New aspects in the therapy of thrombosis and prevention of recurrence in pregnancy].
    Voigt T; Voigt H; Scheel H; Wegner H
    Zentralbl Gynakol; 1987; 109(3):169-72. PubMed ID: 3564756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acquired resistance to prolonged treatment with intravenous "Arvin" (ancrod).
    Thomson NC; Hutcheon AW; Dagg JH
    Br J Clin Pract; 1976; 30(11-12):232-3. PubMed ID: 1008987
    [No Abstract]   [Full Text] [Related]  

  • 57. Heparin-induced thrombosis treated with ancrod.
    Brennan MB; MacKean GL
    Can J Surg; 1994 Apr; 37(2):161-4. PubMed ID: 8156472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bromelines in phlebology].
    Tessler L
    Phlebologie; 1965; 18(2):137-41. PubMed ID: 5829341
    [No Abstract]   [Full Text] [Related]  

  • 59. [Quality of life in peripheral arterial occlusive disease. Multicenter study of quality of life characteristics with a newly developed disease-specific questionnaire].
    Heidrich H; Bullinger M; Cachovan M; Creutzig A; Diehm C; Gruss JD; Kirchberger I; Loeprecht H; Rogatti W
    Med Klin (Munich); 1995 Dec; 90(12):693-7. PubMed ID: 8583985
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical and coagulation physiological studies on a protease from Aspergillus ochraceus (preliminary report)].
    Vogel G; Grossmann K; Huyke R; Zuber W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(1):125-31. PubMed ID: 4134261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.